

## Financial Tear Sheet

### Corporate Profile

XBiotech is building on a foundation of remarkable new therapies, innovative approaches to commercialization and a commitment to realizing treatments for unmet medical needs worldwide.

### Stock Information

XBIT (Common Stock)	
<b>Exchange</b>	NASDAQ (US Dollar)
<b>Price</b>	\$5.02
<b>Change (%)</b>	▲ 0.16 (3.29%)
<b>Volume</b>	275,092
<b>52 Week Low</b>	\$2.77
<b>Market Cap</b>	\$171,512,627
<b>Rolling EPS</b>	-1.63
<b>PE Ratio</b>	0
<b>Shares Outstanding</b>	35,290,664
Data as of 06/28/17 4:00 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

### Recent News

Date	Title
06/09/17	XBiotech Announces Discontinuation of Phase III Study for Colorectal Cancer Based on Second Interim Analysis
06/01/17	XBiotech Presents Phase III Findings for its Antibody Therapy for Colorectal Cancer at the 2017 ASCO Meeting
05/30/17	Dr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal Cancer

### Upcoming Events

There are currently no events scheduled.

## SEC Filings

Filing Date	Form
06/26/17	4
06/23/17	4/A
06/23/17	4/A
06/23/17	4/A

## Management

John Simard	Founder, President, Chief Executive Officer & Chairman
David J. Combs, Ph.D.	Vice President of Manufacturing
Norma I. Gonzalez	Vice President of Quality
Queena Han, C.P.A., C.G.A.	Vice President of Finance and Human Resources and Secretary
Sushma Shivaswamy, Ph.D.	Vice President of Research and Development
Michael Stecher, M.D.	Medical Director

## Primary IR Contact

James S. Whitehurst  
XBiotech  
**Phone:** +1 512.386.2993  
**Email:** swhitehurst@xbiotech.com

## Board of Directors

John Simard	Founder, President, Chief Executive Officer & Chairman
Fabrizio Bonanni, Dr. Chem.	Director
Thorpe McKenzie	Director
Daniel Vasella, M.D.	Director